Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial
Wei Yee Chan(Royal London Hospital), Neil Rabin(University College London), Claire Roddie(Cancer Institute (WIA)), Elizabeth H. Phillips(University of Manchester), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Gordon Cook(University of Leeds), Laura Clifton‐Hadley(Cancer Research UK), Toyin Adedayo(Cancer Research UK), Matthew Streetly(King's College - North Carolina), Curly Morris(Belfast Health and Social Care Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Dunnya De‐Silva(University of Liverpool), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Josephine Crowe(Royal United Hospital), Stephen Schey(University College Hospital), Nivette Braganca(Cancer Research UK), Jamie Cavenagh(St Bartholomew's Hospital)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719